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Background: Differences between populations might be reflected in their different genetic risk maps to complex diseases, for example, inflammatory bowel
disease. We here investigated the role of known inflammatory bowel disease–associated single nucleotide polymorphisms (SNPs) in a subset of patients with
ulcerative colitis (UC) from the Northeastern European countries Lithuania and Latvia and evaluated possible epistatic interactions between these genetic variants.
Methods: We investigated 77 SNPs derived from 5 previously published genome-wide association studies for Crohn’s disease and UC. Our study panel comprised
444 Lithuanian and Latvian patients with UC and 1154 healthy controls. Single marker case–control association and SNP-SNP epistasis analyses were performed.
Results: We found 14 SNPs tagging 9 loci, including 21q21.1, NKX2-3, MST1, the HLA region, 1p36.13, IL10, JAK2, ORMDL3, and IL23R, to be
associated with UC. Interestingly, the association of UC with previously identified variants in the HLA region was not the strongest association in our
study (P ¼ 4.34 · 1023, odds ratio [OR] ¼ 1.25), which is in contrast to all previously published studies. No association with any disease subphenotype
was found. SNP-SNP interaction analysis showed significant epistasis between SNPs in the PTPN22 (rs2476601) and C13orf31 (rs3764147) genes and
increased risk for UC (P ¼ 1.64 · 1026, OR ¼ 2.44). The association has been confirmed in the Danish study group (P ¼ 0.04, OR ¼ 3.25).
Conclusions: We confirmed the association of the 9 loci (21q21.1, 1p36.13, NKX2-3, MST1, the HLA region, IL10, JAK2, ORMDL3, and IL23R) with
UC in the Lithuanian–Latvian population. SNP-SNP interaction analyses showed that the combination of SNPs in the PTPN22 (rs2476601) and
C13orf31 (rs3764147) genes increase the risk for UC.
(Inflamm Bowel Dis 2013;19:2349–2355)
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U lcerative colitis (UC) is a chronic, relapsing inflammatory con-dition of the colon. It represents 1 of the 2 main subforms of
inflammatory bowel disease (IBD), the other being Crohn’s disease
(CD). IBD is a major burden for health systems in Western countries,
with prevalence rates in North America and Europe ranging from 6 to
243 cases per 100,000 inhabitants for UC and of 3.6 to 214 cases per
100,000 inhabitants for CD.1 The very limited data from the North-
eastern European countries demonstrate low incidence rates of IBD:
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Lithuania, 2.6 CD cases and 6.5 UC cases per 100,000 inhabitants;
Estonia, 5.4 CD cases and 5.7 UC cases per 100,000 inhabitants.2
Although the precise etiology of IBD is unknown, current data sup-
port the hypothesis of a complex interplay between genetic and
environmental factors, the latter being subject of drastic changes
during the last century.3
The past decade has witnessed remarkable success in the
identification of low-penetrance high-frequency susceptibility var-
iants in IBD. It has been estimated that the so far identified risk loci
explain approximately 13.6% disease variance in CD and 7.5%
disease variance in UC4 indicating that a large part of the genetic risk
is still unaccounted for. One of the possible reasons is that part of the
genetic risk in complex human diseases may be due to the poorly
understood systematic epistatic interactions of genetic variants.5,6
The inherited combinations of functional and/or disease-linked com-
mon single nucleotide polymorphisms (SNPs) may additively or
synergistically shape specific biological processes that increase dis-
ease susceptibility.7 Therefore, the effect might be missed if a gene
that functions primarily through a complex mechanism is examined
separately without regard to its potential interactions with other
genes and/or environmental factors.6 Interactions between SNPs in
common human diseases (including IBD8–11) have been investigated
in a hypothesis-free way using genome-wide association studies
(GWAS) data sets. However, only a few well-replicated instances
have been reported so far.12–14
Thus, we aimed to further dissect the genetic background of
UC by confirming and expanding the findings of 5 previously
published IBD GWAS in a UC cohort from Lithuania and Latvia. In
total, 77 SNPs were genotyped in 447 UC cases and 1154 healthy
controls. The selected SNP set partially overlaps with the hits
reported in the 2 recent UC meta-analyses (10 overlapping loci with
McGovern et al study8; 23 loci with Anderson et al study15).
MATERIALS AND METHODS
Subjects
The study included 447 unrelated patients with UC (average
age 6 SD ¼ 44.4 6 16.5) and 1154 healthy controls (average
age 6 SD ¼ 40.2 6 12.7) of Caucasian ethnicity. The recruitment
of study individuals was performed in 7 hospitals from Lithuania
(Hospital of Lithuanian University of Health Sciences Kaunas Clinics,
Vilnius University Hospital Santariskiu Clinics, M. Marcinkevicius
Hospital in Vilnius, Klaipeda University Hospital, Klaipeda
Seamen’s Hospital, Republican Panevezys Hospital, and Republi-
can Siauliai Hospital) and 3 Latvian hospitals in Riga (P. Stradina
Clinical University Hospital, Latvian Maritime Medicine Center in
Riga, and Riga Eastern Clinical University Hospital), during the
years 2003 through 2009. The Lithuanian control individuals were
recruited from the National Blood Center, whereas recruitment of
the Latvian healthy individuals was performed at the participating
clinical centers from Latvia. Although blood bank donors are
a selected group compared with population controls, they are
regularly and confidently being used in genetic association
studies.10 Principal component plot also indicated a tight overlap
between cases and controls (Fig., Supplemental Digital Content
1, http://links.lww.com/IBD/A255). The diagnosis of UC was
based on standard clinical, endoscopic, radiological, and histolog-
ical criteria.16 A subgroup of patients with UC and controls used in
this study has been used and characterized in previous studies.15,17
The full demographic and phenotypic descriptions of both study
groups are summarized in Table, Supplemental Digital Content 2,
http://links.lww.com/IBD/A256. The clinical characteristics pro-
vided in the table are given according to the Montreal classifica-
tion.18 All phenotypic data were collected blind to the results of the
genotypic data. Written informed consent from all participants and
approval of the ethics committees was obtained.
For replication of the SNP-SNP interaction between
PTPN22 (rs2476601) and C13orf31 (rs3764147), Danish and
German study groups were tested for an association. The Danish
study population consisted of 124 patients with UC and 92
healthy blood donors of Caucasian ethnicity overlapping with
samples that have been used in a previous study.19 The German
study panel comprised 892 patients with UC and 1901 controls of
Caucasian ethnicity. This panel has been used and described in
previous publications.20,21
Genotyping and SNP Selection
SNPs from 5 original CD or UC GWAS (CD: Franke
et al,22 WTCCC/Parkes et al,10,23 and Barrett et al24; UC: Franke
et al20 and Silverberg et al25), along with SNPs in previously
IBD-associated genes (NOD2,26,27 DLG5,28 IL23R,29 SLC22A4
and SLC22A5,30 TNFSF15,31 PTGER4,32MST1,33 and ATG16L134),
were selected for genotyping. Three SNP genotyping assays
(rs11805303,20 rs287094616,25 and rs1080104710,23) failed to
design; therefore, the final genotyping panel included 77 SNPs
from 46 different loci (Table, Supplemental Digital Content 3,
http://links.lww.com/IBD/A257). Of these 46 loci, 36 have
meanwhile been reported as genome-wide significant in the most
recent meta-analyses (marked bold in the Table, Supplemental Dig-
ital Content 3, http://links.lww.com/IBD/A257).8,15
Genotyping was performed at the Institute for Clinical
Molecular Biology (Christian-Albrechts University, Kiel, Germany)
by ligation-based SNPlex and TaqMan technologies from Life
Technologies (formerly Applied Biosystems, Foster City, CA)
according to the manufacturer’s recommendations. Genotype
assignments were manually confirmed by visual inspection with
the Genemapper 4.0 compatible with the SNPlex system and
SDS 2.3 software compatible with the TaqMan system.
Statistical Analysis
The combined screening panel of 447 cases and 1154
controls had 80% power to detect an odds ratio (OR) of $1.44 at
the 5% significance level, assuming a frequency of the disease-
associated allele of $20% in the controls (Fig., Supplemental Dig-
ital Content 4, http://links.lww.com/IBD/A258). Quality assess-
ments and statistical analysis of the genotyping data were
performed using PLINK software version 1.07.35 Individuals with
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.10% missing genotypes and SNPs with a call rate ,90% or
deviation from Hardy–Weinberg equilibrium in the controls (P ,
0.05) were excluded from further analysis. In total, 99.6% of all
cases and controls were successfully genotyped. The average gen-
otyping rate across all samples was 98%. One SNP (rs2289310)
failed genotyping, resulting in a total of 76 SNPs that were analyzed
in 444 UC cases and 1154 controls.
Differences in allele frequencies between cases and controls
were calculated in the combined Lithuanian and Latvian study sample,
using the Cochrane–Mantel–Haenszel test together with the Breslow–
Day test for heterogeneity of ORs. Six of the 76 SNPs (rs2925757,
rs10077785, rs2076756, rs7868736, rs10974944, and rs2066847)
showed heterogeneity of ORs between the Lithuanian and Latvian
UC study groups (PBD , 0.05) and were therefore excluded from
further analyses. Nevertheless, the recent study by Nelis et al36 showed
that the 3 Baltic countries (Lithuania, Latvia, and Estonia), Poland, and
Western Russia together form a genetic cluster (inflation factor l ¼
1.23), thereby indicating that our 2 study populations can be combined
in an association analysis without risking too many false-negative and
false-positive results due to population stratification. In the case–
control association analysis, two significance criteria were applied:
(1) replication of the SNPs that were associated with UC at
genome-wide significance (P , 5 · 1028) in previous studies was
defined as an association at a level of P , 0.05 with the same risk
allele identified in the index studies; (2) new association to UC—
a case–control association at a level of P , 5 · 1028 was required
for a SNP to be considered as a new UC locus.
Subphenotypes of UC (disease localization [defined macro-
scopically as extensive, left-sided, or proctitis only] and extraintestinal
manifestations), disease modifiers (age at diagnosis and family history
of disease), and disease outcome measures (surgery and treatment
using biological therapy) were inspected in within-case analyses. The
x2 test was used to detect association between each binary phenotype
and the genotyped SNPs. P values were adjusted for multiple com-
parisons based on the Bonferroni procedure (correction was applied
for the number of complementary subgroups of patients).
SNP-SNP epistasis for our case–control population-based
sample was calculated using the –fast-epistasis command as imple-
mented in PLINK. The latter provides a logistic regression test for
interaction that assumes an allelic model for both the main effects
and the interactions. This test is based on a Z-score for the difference
in SNP-SNP association (OR) between cases and controls and fol-
lows a standard normal distribution under the multiplicative model
of no interaction. All pairwise combinations of SNPs were tested.
Again, P values were adjusted for multiple testing by Bonferroni
correction (2404 independent tests, corrected P ¼ 2 · 1025).
RESULTS
Allelic Association Analysis in UC
Combined analysis of the 2 study groups revealed 14 SNPs
from 9 independent loci (21q21.1, 1p36.13, NKX2-3, MST1, the
HLA region, ORMDL3, IL10, JAK2, and IL23R) to be associated
with UC (Table 1 and Table, Supplemental Digital Content 5,
http://links.lww.com/IBD/A259). All identified allelic association
signals were in the same direction as reported in previous IBD
studies.10,20,22–25 All 9 loci have been reported as genome-wide
significant, by the recent UC meta-analyses.15
The statistical power of our study to detect a disease
association (assuming the same effect size as documented in
original studies) is given in Table 1 for each SNP. Estimated
power varied widely between SNPs, with the highest power cal-
culated for the 2 known IBD variants in NKX2-3 and BSN; for the
known UC loci, the highest calculated power had HLA and IL10.
For 21 SNPs, we had a power of.80% out of which 6 SNPs were
successfully replicated (Table 1 and Table, Supplemental Digital
Content 5, http://links.lww.com/IBD/A259).
Genetic Association with UC Subphenotypes
We tested all UC-associated SNPs with phenotypic char-
acteristics such as age of onset, gender, disease localization,
extraintestinal manifestations, family history of IBD, surgery
treatment, and treatment using biological therapy. No significant
associations were found for the subphenotypes under study
following correction for multiple testing.
SNP-SNP Interaction Analysis
SNP-SNP interaction, known as epistasis, has been
investigated among all candidate SNPs that passed quality
control, using a logistic regression test (Table, Supplemental
Digital Content 6, http://links.lww.com/IBD/A260). We found
a significant association that withstood Bonferroni correction
between rs2476601 and rs3764147 (P ¼ 1.64 · 1026, OR ¼
2.44) under the assumption of a nonadditive genetic model. The
interacting SNPs were located in genes PTPN22 (rs2476601)
and C13orf31 (rs3764147), respectively (for the interaction pat-
tern of this SNP pair, see Table 2).
The 2 SNPs had a minor allele frequency of 14.3%
(rs2476601, allele A) and 27.5% (rs3764147, allele G) in the
control group, and the affected individuals showed an excess of
genotype pairs AA–AG, GA–GG, and GA–AG. Risks, relative to
the most common homozygous genotype GG–AA, are reported in
Table 2. For genotypes GA–GG and GA–AG, the relative risks
were significantly larger than 1, with OR ¼ 2.24 (95% CI: 1.09–
4.64, P ¼ 0.03) and OR ¼ 1.48 (95% CI: 1.02–2.16, P ¼ 0.04),
respectively. The combined OR for the 2 genotypes (GA–GG and
GA–AG) was 1.60 (95% CI: 1.13–2.26, P ¼ 8.13 · 1023).
Although genotype AA–AG did not reach the level of significance
(P ¼ 0.15, OR ¼ 2.10, 95% CI: 0.75–5.87), possibly due to its low
frequency, the OR was still larger than 1, indicating an increased
risk. The joint OR of the 3 risk genotypes was 1.63 (95% CI: 1.16–
2.29, P ¼ 4.32 · 1023), demonstrating that the 3 specific allele
combinations of the SNPs rs2476601 and rs3764147 confer an
elevated risk for UC in the Lithuanian–Latvian sample set.
The evidence for replication of the interaction was sought
in the German (892 UC cases, 1901 controls) and Danish (124 UC
cases, 92 controls) study panels. The 2 SNPs had a minor allele
Inflamm Bowel Dis  Volume 19, Number 11, October 2013 Replication Study of UC Risk Loci
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frequency of 11.1% and 13% (rs2476601, allele A) and 25.1%
and 22.8% (rs3764147, allele G) in the German and Danish control
groups, respectively. The PTPN22 and C13orf31 SNP pair
was confirmed to increase UC risk in the Danish study group
(P ¼ 0.04, OR ¼ 3.25, Table, Supplemental Digital Content 7,
http://links.lww.com/IBD/A261), whereas in the German study
group, no association was found (P ¼ 0.45, OR ¼ 0.89, Table,
Supplemental Digital Content 8, http://links.lww.com/IBD/A262).
However, possibly due to the small sample size, none of the geno-
type pairs was overrepresented in the Danish UC group (Table,
Supplemental Digital Content 7, http://links.lww.com/IBD/A261).
Although the tendency for an increase in frequency of genotype
pairs GA–AG and GG–GG in UC group could be observed. The
risk-increasing genotype pair GA–GG was not detected in
the Danish control group but was present in 1.1% of the UC
cases, whereas AA–AG was not determined neither in the cases
nor in the controls.
DISCUSSION
In the past 5 years, GWAS in CD and UC have identified
many novel susceptibility loci. Our study represents the first
comprehensive analysis of the contribution of previously reported
genetic risk factors10,20,22–25 to UC susceptibility in a low-incidence
population of Northeastern Europe—Lithuania and Latvia.2 The
collaboration between these 2 small Northeastern European coun-
tries (combined study panel of 1601 individuals) was initiated to
form a large IBD study sample with enough study power for the
TABLE 1. Loci Showing Significant Association With UC in a Case–Control Analysis
Position (bp) dbSNP ID Gene of Interest
A1 AFA1
PBD PCMH OR (95% CI) PowerA2 Control Case
1p36.13 (20,142,866) rs380630825 RNF18 T 0.45 0.47 2.40 · 1024 0.74 (0.63–0.87) 84.93%
C 0.38
1p36.13 (20,171,860) rs642683325 — A 0.49 0.85 6.01 · 1023 1.25 (1.07–1.46) 92.48%
G 0.54
1p31.3 (67,702,526) rs1146580424,25,29 IL23R G 0.05 0.49 0.012 0.58 (0.38–0.89) 51.74%
T 0.03
1p31.3 (67,705,958) rs1120902625,29 IL23R A 0.07 0.51 2.16 · 1023 0.55 (0.38–0.81) 63.14%
G 0.04
1q32.1 (206,939,904) rs302450520 IL10 A 0.13 0.17 1.04 · 1023 1.43 (1.16–1.77) 80.83%
G 0.17
3p21.31 (49,721,532) rs319799920,33 MST1 T 0.23 0.65 3.21 · 1023 1.32 (1.10–1.58) 50.56%
C 0.28
6p21.32 (32,363,844) rs926848020 BTNL2 T 0.21 0.17 0.025 0.79 (0.65–0.97) 47.05%
C 0.17
6p21.32 (32,429,758) rs926885820 HLA-DRA C 0.24 0.49 0.011 0.78 (0.64–0.94) 91.93%
T 0.19
6p21.32 (32,431,147) rs926887720 HLA-DRA T 0.51 0.98 4.34 · 1023 1.25 (1.07–1.47) 96.13%
C 0.56
6p21.32 (32,433,167) rs239518525 HLA-DRA T 0.24 0.41 6.44 · 1023 0.76 (0.63–0.93) 76.01%
G 0.19
9p24.1 (4,981,602) rs1075866924 JAK C 0.36 0.09 8.08 · 1025 1.38 (1.17–1.62) 16.71%
A 0.43
10q24.2 (101,291,593) rs1119014010,23,24 NKX2-3 T 0.46 1.00 7.27 · 1023 1.25 (1.06–1.48) 82.85%
C 0.52
17q12 (38,040,763) rs287250724 ORMDL3 A 0.41 0.56 1.24 · 1024 1.36 (1.16–1.59) 17.42%
G 0.49
21q21.1 (16,805,220) rs173613524 — C 0.43 0.89 8.01 · 1026 0.69 (0.59–0.81) 29.68%
T 0.34
Detailed results for all 70 SNPs can be found in Table, Supplemental Digital Content 5, http://links.lww.com/IBD/A259. Nucleotide positions refer to NCBI build 37. A1 denotes
the minor allele and A2 is the common allele. The respective allele frequencies are shown for allele A1 (AFA1). P values were obtained from the Breslow–Day test (PBD) and the
Cochran–Mantel–Haenzsel test (PCMH). Odds ratios and 95% confidence intervals for carriership of allele A1 are shown as OR (95% CI). The power of this study to replicate the
association at 0.05 significance level is shown (AF and OR presented in the original studies were used for calculations).
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analysis of moderate effect size susceptibility variants. A recent
study on the genetic differences in European populations, investi-
gating the detailed structure of the Baltic countries and other North-
eastern European populations, showed that the 3 Baltic countries
(Lithuania, Latvia, and Estonia), Poland, and Western Russia
together form a genetic cluster, and hence negligible population
structure exists, which proves that our 2 study populations can be
combined in association analyses.36
In our Lithuanian–Latvian case–control study of 444 UC
cases and 1154 controls, we found 9 robust genetic risk loci to
be associated with UC. The allele frequencies and contributed
risks of the respective SNPs in the risk loci were similar to
previous reports in other Caucasian populations.9,20,25,37–42 The
reported risk loci are implemented in the pathogenesis of other
immune-related diseases as well, e.g., ORMDL3 has been pre-
viously shown to be associated with asthma, type 1 diabetes,
psoriasis, CD and IL10 with type 1 diabetes, CD, systemic lupus
erythematosus, Behçet’s disease. Despite of the long known and
very strong association between UC and the HLA region, and
the sufficient power of our study for the respective SNPs, the
HLA variants were not between the strongest associated SNPs
in our Lithuanian–Latvian cohort. However, a significant differ-
ence of effect between our study and previously published re-
ports could not be detected as the 95% confidence intervals (CIs)
of the ORs overlap (our study: OR ¼ 1.25 and 95% CI ¼ 1.07–
1.47 versus Franke et al20: OR ¼ 1.45 and 95% CI ¼ 1.33–1.58).
Finally, several previously reported risk loci, including STAT3,
IL12B, PTPN2, NELL1, and ARP2C were not replicated in our
study, which of course does not necessarily mean that these are not
UC-associated genes in the Baltic population but may only reflect
a lack of statistical power or confounding factors such as different
environmental factors.
A number of studies have demonstrated the presence of
gene–gene interactions in complex human diseases, including
IBD. The epistasis analyses in IBD have been performed
between pathway-related genes,43,44 genes that were individu-
ally associated with IBD,45,46 and in a hypothesis-free way using
GWAS and GWAS meta-analyses data.8–11 However, none of
the findings were replicated in the independent sample sets. In
the frames of this study, we investigated the impact of all pos-
sible studied SNP pairs, including those that were not associated
with UC in our single marker case–control analysis. We were
able to reveal a statistically significant interaction between 2
SNPs (rs2476601 and rs3764147) that were not associated with
UC in the single marker association analysis. The association
was only confirmed in the small Danish study group but not in
the large German cohort. This indicates a possible role of pop-
ulation differences or of a false-positive association due to the
small study and replication panel size. Therefore, further replication
in larger future studies is warranted before this finding can be
considered confirmed. The interacting SNPs are located in the genes
PTPN22 (rs2476601) and C13orf31 (rs3764147) and are both coding
mutations (rs2476601: synonymous; rs3764147: missense). Both in-
teracting regions have been related to the development of autoim-
mune diseases (PTPN22: CD,24 type 1 diabetes, rheumatoid arthritis,
systemic lupus erythematosus, Graves’ disease, autoimmune thyroid
disease, alopecia areata, juvenile idiopathic arthritis, and Hashimoto’s
thyroiditis47; C13orf31: CD24 and leprosy48).
PTPN22 encodes a lymphoid-specific protein tyrosine phos-
phatase (LYP), a member of a family of proteins involved in sup-
pressing spontaneous T-cell activation.49 PTPN22 is expressed in
many hematopoietic cell types, notably T cells. The rs2476601 risk
allele is a gain-of-function mutation that results in a higher catalytic
activity of the phosphatase and more potent negative regulation of
T-cell activation.50,51 By contrast, knockout mice (Lyp is the mouse
ortholog of PTPN22) have an increased T-cell activation in combi-
nation with an increased production of antibodies.52 The biological
functions of the C13orf31 gene product are not known. However,
TABLE 2. Genotype Counts for the SNP Pair (rs2476601, rs3764147) in Patients with UC and the Calculated ORs




Controls GG 407 (36.3%) 357 (31.9%) 63 (5.6%)
GA 161 (14.4%) 92 (8.2%) 16 (1.4%)
AA 17 (1.5%) 8 (0.7%) 0
Ulcerative colitis GG 170 (39%) 119 (27.3%) 19 (4.4%)
GA 45 (10.3%) 57 (13.1%) 15 (3.4%)
AA 3 (0.7%) 7 (1.6%) 1 (0.2%)
OR (95% CI) GG 1 0.80 (0.61–1.05) 0.72 (0.42–1.24)
GA 0.67 (0.46–0.97) 1.48 (1.02–2.16) 2.24 (1.09–4.64)
AA 0.42 (0.12–1.46) 2.10 (0.75–5.87) NA
ORs for the genotypes reaching the level of significance (P , 0.05) are presented in bold.
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because C13orf31 polymorphisms were previously found to be
associated with CD and leprosy, it has been suggested that this
locus might be involved in mycobacteria clearance.48
To further investigate the possible interaction between
PTPN22 and C13orf31, we performed an in silico pathway analysis
(“In silico prediction analysis,” Supplemental Digital Content 9,
http://links.lww.com/IBD/A263), which indicated that both genes
could be connected through coexpression and protein–protein inter-
action (i.e., physical interaction) pathways (Fig., Supplemental Dig-
ital Content 10, http://links.lww.com/IBD/A263). The most
significant molecular processes predicted by the program were the
regulation of positive T-cell activation and segregation of the TCR
complex, which mainly affect immune-mediated regulatory pro-
cesses and cell activation (lymphocyte, T cell). These processes
are mainly linked to the query gene PTPN22.
Taken together, our study results support the previously
proposed functional implications of the genetic associations in
the pathogenesis of UC, i.e., the importance of gene sets
that influence barrier function, transcriptional regulation, cell-
specific innate responses, and regulate adaptive immunity.
Although we did not find an association between IBD variants
and phenotypic characteristics, including age of onset, gender,
and family history of IBD, we could show that SNPs that were
not associated with disease in a single marker analysis contribute
to the overall disease risk by epistatic effects. However,
functional and further replication studies are needed to confirm
the potential protein–protein interactions because statistically sig-
nificant SNP-SNP epistasis does not necessarily mirror biological
interactions. Finally, the contribution of the HLA region to
genetic susceptibility to UC will require more comprehensive
analyses in a larger cohort from Northeastern Europe by using
a dense HLA marker set.
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